Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 3/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29835952 | 1.00 | HTR2A (0.44) | HTR2AHTR2CIDO1TAAR1L3MBTL1 | |
| SCHEMBL29792655 | 0.82 | TAAR1 (0.52) | HTR2AHTR2CIDO1TAAR1L3MBTL1 | |
| SCHEMBL8926 | 0.82 | TAAR1 (0.52) | HTR2AHTR2CIDO1TAAR1L3MBTL1 | |
| SCHEMBL172225 | 0.82 | HTR2A (0.46) | HTR2AHTR2CIDO1TAAR1L3MBTL1 | |
| SCHEMBL467588 | 0.81 | IDO1 (0.55) | IDO1TAAR1L3MBTL1CA12CA1 | |
| SCHEMBL422832 | 0.80 | HTR2A (0.44) | HTR2AHTR2CIDO1TAAR1L3MBTL1 | |
| Bromide SCHEMBL15741709 | 0.80 | TAAR1 (0.50) | HTR2AHTR2CIDO1TAAR1L3MBTL1 | |
| SCHEMBL489913 | 0.80 | HTR2A (0.48) | HTR2AHTR2CIDO1TAAR1L3MBTL1 | |
| SCHEMBL29783095 | 0.80 | HTR2A (0.48) | HTR2AHTR2CIDO1TAAR1L3MBTL1 | |
| SCHEMBL17351757 | 0.80 | IDO1 (0.46) | HTR2AHTR2CIDO1TAAR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3172202-B1 | HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | BOEHRINGER INGELHEIM INT (DE) | 2020-01-29 | — | — | EP | disclosed |
| EP-3205648-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | Seragon Pharmaceuticals, Inc. (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-3205648-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | Seragon Pharmaceuticals, Inc. (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-2580210-B1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS INC (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-2580210-B1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS INC (US) | 2017-03-01 | — | — | EP | disclosed |
| US-9353090-B2 | Heterocyclic carboxylic acids as activators of soluble guanylate cyclase | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-31 | — | — | US | disclosed |
| US-9353090-B2 | Heterocyclic carboxylic acids as activators of soluble guanylate cyclase | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-31 | — | — | US | disclosed |
| US-20160024059-A1 | HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-28 | — | — | US | disclosed |
| US-20160024059-A1 | HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-28 | — | — | US | disclosed |
| WO-2016014463-A1 | HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-28 | — | — | WO | disclosed |
| EP-1670458-A1 | 1-AMINO-2-OXY-SUBSTITUTED TETRAHYDRONAPHTALENE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, AND THEIR USE AS ANTIPHLOGISTICS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-21 | — | — | EP | disclosed |
| US-20050272823-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-12-08 | — | — | US | disclosed |
| US-20050209324-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-09-22 | — | — | US | disclosed |
| US-20050171109-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-08-04 | — | — | US | disclosed |
| WO-2005034939-A1 | 1-AMINO-2-OXY-SUBSTITUTED TETRAHYDRONAPHTALENE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, AND THEIR USE AS ANTIPHLOGISTICS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-04-21 | — | — | WO | disclosed |
| US-5886016-A | ANTIINFLAMMATORY AGENT WITH MINIMAL SIDE EFFECTS FOR TREATING ARTHRITIS | G.D. SEARLE & CO. (US) | 1999-03-23 | — | — | US | disclosed |
| US-5670532-A | Pyrazolyl derivatives for the treatment of inflammation | G. D. SEARLE & CO. (US) | 1997-09-23 | — | — | US | disclosed |
| US-5565482-A | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS | G.D. SEARLE & CO. (US) | 1996-10-15 | — | — | US | disclosed |
| US-5547975-A | ANTIARTHRIC AGENTS, ANALGESICS AND ANTIPYRETICS; INHIBITORS OF CYCLOOXYGENASE II; SIDE EFFECT REDUCTION | G.D. SEARLE & CO. | 1996-08-20 | — | — | US | disclosed |
| WO-1996009304-A1 | BENZOPYRANOPYRAZOLYL DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024059-A1 | HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | ADCY9, ADCY7, GUCY1B1 | HTR2A 1158/4885HTR2C 1835/4885IDO1 3949/4885 |
| US-20050171109-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | TNF, DHPS, PTGES | HTR2A 1071/4885HTR2C 1540/4885IDO1 1029/4885 |
| US-20050272823-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | DHPS, TNF, PTGES | HTR2A 1523/4885HTR2C 1886/4885IDO1 755/4885 |
| US-20050209324-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | TNF, DHPS, PTGES | HTR2A 1071/4885HTR2C 1540/4885IDO1 1029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.